Knowing When to Call It Quits in Drug Development and Healthcare Innovations
0:00
34:28
The drug development process is costly, time consuming and laden with risk—with only 1% of drugs making it from pre-clinical all the way to market, according to Pharma Intelligence. To beat these odds, life sciences leaders must know when to continue funding a promising, new product and when to call it quits.
Tune in for insights into:
- Why a “fast to failure” mentality is key to a successful development pipeline
- How leaders can redivert organizational resources after ending a program
- Why drug development failures can ultimately lead to positive outcomes
Weitere Episoden von „BDO's Health & Life Sciences Rx Podcast“
Verpasse keine Episode von “BDO's Health & Life Sciences Rx Podcast” und abonniere ihn in der kostenlosen GetPodcast App.